hydroxychloroquine + ipilimumab + nab-paclitaxel + gemcitabine

This is a **combination regimen** of four agents: - **Hydroxychloroquine**: a small molecule traditionally used as an antimalarial and in autoimmune diseases, studied off-label as an autophagy inhibitor in cancer research. - **Ipilimumab**: a monoclonal antibody immune checkpoint inhibitor targeting CTLA-4, used in cancer immunotherapy to promote T-cell activation and anti-tumor responses[1][3][5]. - **Nab-paclitaxel**: an albumin-bound nanoparticle formulation of paclitaxel, a microtubule inhibitor that impedes cell division, approved for use in combination with gemcitabine in metastatic pancreatic cancer[4][6]. - **Gemcitabine**: a nucleoside analog antimetabolite that inhibits DNA synthesis, commonly used as chemotherapy for pancreatic and other cancers. This combination is investigational and used in cancer research, primarily pancreatic cancer and other solid tumors as a multi-mechanistic approach combining immunotherapeutic, chemotherapeutic, and autophagy modulation strategies.